CriticalReversible MAO-A inhibitor (RIMA)×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
Trazodone inhibits serotonin reuptake at the presynaptic level and blocks 5-HT2A serotonin receptors at the postsynaptic level (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label classes it as a selective serotonin reuptake inhibitor (trazodone label, US Food and Drug Administration, FDA). Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide SmPC, AEMPS). MAO inhibitors impair serotonin metabolism and, together with serotonergic drugs such as trazodone, raise the risk of serotonin syndrome (trazodone FDA label). The elimination half-life of moclobemide is about 3 hours (moclobemide SmPC, AEMPS).
Symptoms
Serotonin syndrome can be life-threatening (trazodone label, US Food and Drug Administration, FDA). It presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high temperature), neuromuscular signs (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting or diarrhoea (trazodone FDA label). The moclobemide SmPC reports isolated cases of a severe combination of hyperthermia, confusion, hyperreflexia and myoclonus when moclobemide was given with other antidepressants (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish trazodone SmPC describes serotonin syndrome and neuroleptic malignant syndrome with monoamine oxidase inhibitors and other serotonergic drugs (trazodone SmPC, AEMPS).
Management
The US trazodone label contraindicates the combination. Trazodone is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping them (trazodone label, US Food and Drug Administration, FDA), and moclobemide is an MAOI according to its own summary of product characteristics (moclobemide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish documents are less strict: the trazodone SmPC does not recommend combining trazodone with MAOIs, although it notes that some doctors prescribe them together (trazodone SmPC, AEMPS), and the moclobemide SmPC does not name trazodone and asks for caution when other antidepressants that increase serotonin are added to moclobemide (moclobemide SmPC, AEMPS). The documents give different switching intervals: the US trazodone label requires at least 14 days between stopping an MAOI antidepressant and starting trazodone, and the same in the other direction (trazodone FDA label). The Spanish trazodone SmPC does not recommend starting trazodone during the first 2 weeks after stopping an MAOI or giving an MAOI one week after stopping trazodone (trazodone SmPC, AEMPS), while the moclobemide SmPC allows another antidepressant to be started the day after moclobemide is stopped (moclobemide SmPC, AEMPS). If signs of serotonin syndrome appear, stop trazodone and other serotonergic drugs at once and start supportive symptomatic treatment (trazodone FDA label; trazodone SmPC, AEMPS). If hyperthermia, confusion, hyperreflexia and myoclonus occur together, keep the patient under medical observation, in hospital if needed (moclobemide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- AEMPS: Ficha técnica: Trazodona, Deprax 100 mg (nº registro 78762), sección 4.5 (2023)– AEMPS, CIMA, nº registro 78762 (Deprax 100 mg comprimidos recubiertos con película, Angelini Pharma España), revisión 11/2023, secciones 4.4, 4.5 y 5.1